You Searched For: 3-Fluoro-4-iodobenzyl+alcohol


7,192  results were found

SearchResultCount:"7192"

Sort Results

List View Easy View

Rate These Search Results

Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Supplier: Biotium
Description: Recognizes a 67 kDa transmembrane protein, which is identified as CD5 (HLDA I; WS Code T 29HLDA III; WS Code T 530). The CD5 antigen is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in T cell areas. Anti-CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms.

Catalog Number: (BNUM0862-50)
Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).
UOM: 1 * 50 µl


Catalog Number: (BOSSBS-11884R-CY5)
Supplier: Bioss
Description: The Drosophila atonal gene produces a protein with basic helix loop helix (bHLH) domains that plays an essential role in the development of the Drosophila nervous system. Mammalian atonal homolog 2 (MATH-2) is a helix-loop-helix (HLH) transcription factor that is structurally homologous to the product of Drosophila atonal gene. MATH-2 is a 337 amino acid protein with an atonal-related basic HLH domain. In mice, expression of MATH-2 takes place by embryonic day 11.5 and initially localizes to the wall of brain vesicles and in the spinal cord. It is expressed in the cortical plate and the mantle layer in the developing central nervous system, and is limited to the nervous system in adults. Adult mouse cerebrums produce a high level of MATH-2 RNA with lower levels in other neuronal tissues. Research studies suggest that MATH-2 may function as a trans-acting factor involved in the development and maintenance of the mammalian nervous system.
UOM: 1 * 100 µl


Supplier: Biotium
Description: Recognizes a protein of 95 kDa, identified as CD19. CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Supplier: Biotium
Description: Recognizes a protein of 95 kDa, identified as CD19. CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Supplier: BUCHI
Description: Cold trap mantle for condenser C, P+G-LT, For: Rotary evaporator R-210 / R-215

Supplier: Biotium
Description: Recognizes a protein of 95 kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Supplier: Biotium
Description: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Supplier: Biotium
Description: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Supplier: Biotium
Description: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Supplier: Biotium
Description: Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4. HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center-derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Inquire for Price
Stock for this item is limited, but may be available in a warehouse close to you. Please make sure that you are logged in to the site so that available stock can be displayed. If the call is still displayed and you need assistance, please call us on 0800 22 33 44.
Stock for this item is limited, but may be available in a warehouse close to you. Please make sure that you are logged in to the site so that available stock can be displayed. If the call is still displayed and you need assistance, please call us on 0800 22 33 44
Additional Documentation may be needed to purchase this item. A VWR representative will contact you if needed.
Additional Documentation may be needed to purchase this item. A VWR representative will contact you if needed.
This product has been blocked by your organisation. Please contact your purchasing department for more information.
The original product is no longer available. The replacement shown is available.
Product(s) marked with this symbol are discontinued - sold till end of stock. Alternatives may be available by searching with the VWR Catalogue Number listed above. If you need further assistance, please call VWR Customer Service on 0800 22 33 44.
49 - 64 of 7,192
no targeter for Bottom